Evidence map›Paper›PMID 36349017›Full record

ReviewRSC advances2022

Fluorescence immunosensor based on functional nanomaterials and its application in tumor biomarker detection.

Juanjuan Huang, Fenghuang Wei, Yuling Cui, Li Hou, Tianran Lin

Abstract readReview
In one paragraph

Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juanjuan HuangSchool of Chemistry and Pharmaceutical Science, State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University Guilin 541004 P. R. China houli@gxnu.edu.cn tianranlin@163.com.
Fenghuang WeiSchool of Chemistry and Pharmaceutical Science, State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University Guilin 541004 P. R. China houli@gxnu.edu.cn tianranlin@163.com.
Yuling CuiJinan Center for Food and Drug Control Jinan 250102 Shandong China.
Li HouSchool of Chemistry and Pharmaceutical Science, State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University Guilin 541004 P. R. China houli@gxnu.edu.cn tianranlin@163.com.ORCID https://orcid.org/0000-0001-8540-452X
Tianran LinSchool of Chemistry and Pharmaceutical Science, State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University Guilin 541004 P. R. China houli@gxnu.edu.cn tianranlin@163.com.ORCID https://orcid.org/0000-0003-1228-2095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An immunosensor is defined as an analytical device that detects the binding of an antigen to its specific antibody by coupling an immunochemical reaction to the surface of a device called a transducer. Fluorescence immunosensing is one of the most promising immunoassays at present, and has the advantages of simple operation, fast response and high stability. A traditional fluorescence immunosensor often uses an enzyme-labelled antibody as a recognition unit and an organic dye as a fluorescence probe, so it is easily affected by environmental factors with low sensitivity. Nanomaterials have unique photostability, catalytic properties and biocompatibility, which open up a new path for the construction of stable and sensitive fluorescence immunosensors. This paper briefly introduces different kinds of immunosensors and the role of nanomaterials in the construction of immunosensors. The significance of fluorescent immunosensors constructed from functional nanomaterials to detect tumor biomarkers was analyzed, and the strategies to further improve the performance of fluorescent immunosensors and their future development trend were summarized.

Identifiers

PMID36349017
PMCPMC9624183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.